Table 4 HI seroconversion rates and seroconversion factors in response to vaccination
Group | Day | N | A/Brisbane | A/Uruguay | B/Brisbane |
|---|---|---|---|---|---|
% seroconversion rate (95% CI)a | |||||
TIV/AS03 (≥65) | 21 | 62 | 58 (45–71) | 84 (72–92) | 71 (58–82) |
42 | 61 | 54 (41–67) | 79 (66–88) | 62 (49–74) | |
180 | 62 | 26 (15–39) | 58 (45–71) | 35 (24–49) | |
TIV(≥65) | 21 | 66 | 48 (36–61) | 76 (64–86) | 58 (45–70) |
42 | 65 | 38 (27–51) | 68 (55–79) | 54 (41–66) | |
180 | 66 | 24 (14–36) | 42 (30–55) | 33 (22–46) | |
TIV(18-40) | 21 | 43 | 67 (51–81) | 77 (61–88) | 67 (51–81) |
42 | 44 | 66 (50–80) | 68 (52–81) | 57 (41–72) | |
180 | 43 | 53 (38–69) | 46 (31–62) | 46 (31–62) | |
Seroconversion factor (95% CI) a | |||||
TIV/AS03 (≥65) | 21 | 62 | 6.4 (4.5–9.0) | 15 (11–22) | 7.6 (5.6–10) |
42 | 61 | 5.1 (3.7–7.0) | 12 (8.5–17) | 5.4 (4.0–7.2) | |
180 | 62 | 2.3 (1.8–3.0) | 5.5 (4.1–7.3) | 2.8 (2.2–3.4) | |
TIV(≥65) | 21 | 66 | 4.7 (3.4–6.6) | 9.4 (6.6–13) | 5.2 (3.8–7.1) |
42 | 65 | 3.9 (2.8–5.4) | 6.4 (4.7–8.6) | 4.1 (3.1–5.4) | |
180 | 66 | 2.2 (1.7–3.0) | 3.4 (2.5–4.6) | 2.5 (1.9–3.1) | |
TIV(18-40) | 21 | 43 | 11 (6.3–18) | 11 (7.2–18) | 7.4 (4.7–12) |
42 | 44 | 8.9 (5.3–15) | 7.9 (5.3–12) | 5.8 (3.7–8.9) | |
180 | 43 | 4.6 (2.9–7.2) | 4.5 (3.0–6.9) | 4.0 (2.8–5.8) | |